Free Trial
NASDAQ:INZY

Inozyme Pharma (INZY) Stock Price, News & Analysis

Inozyme Pharma logo
$4.00 +0.01 (+0.13%)
As of 03:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Inozyme Pharma Stock (NASDAQ:INZY)

Key Stats

Today's Range
$3.98
$4.00
50-Day Range
$0.92
$3.99
52-Week Range
$0.72
$6.24
Volume
432,067 shs
Average Volume
889,508 shs
Market Capitalization
$257.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.75
Consensus Rating
Hold

Company Overview

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Inozyme Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

INZY MarketRank™: 

Inozyme Pharma scored higher than 53% of companies evaluated by MarketBeat, and ranked 459th out of 924 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Inozyme Pharma has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Inozyme Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Inozyme Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.59) to ($1.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inozyme Pharma is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inozyme Pharma is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Inozyme Pharma has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Inozyme Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    8.49% of the float of Inozyme Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Inozyme Pharma has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Inozyme Pharma has recently decreased by 4.17%, indicating that investor sentiment is improving.
  • Dividend Yield

    Inozyme Pharma does not currently pay a dividend.

  • Dividend Growth

    Inozyme Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.49% of the float of Inozyme Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Inozyme Pharma has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Inozyme Pharma has recently decreased by 4.17%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Inozyme Pharma this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for INZY on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Inozyme Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Inozyme Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.18% of the stock of Inozyme Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    88.30% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Inozyme Pharma's insider trading history.
Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

INZY Stock News Headlines

Inozyme Pharma Inc Ordinary Shares
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.
BMRN to Acquire Inozyme Pharma
See More Headlines

INZY Stock Analysis - Frequently Asked Questions

Inozyme Pharma's stock was trading at $2.77 at the start of the year. Since then, INZY stock has increased by 43.9% and is now trading at $3.9850.
View the best growth stocks for 2025 here
.

Inozyme Pharma, Inc. (NASDAQ:INZY) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.01.

Inozyme Pharma (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Inozyme Pharma's top institutional shareholders include Affinity Asset Advisors LLC (5.99%), Knott David M Jr (1.03%), Pale Fire Capital SE (0.68%) and Aberdeen Group plc (0.51%). Insiders that own company stock include Robert Lorne Hopfner, Pivotal Bioventure Partners Fu, Henric Bjorn Bjarke and Douglas A Treco.
View institutional ownership trends
.

Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inozyme Pharma investors own include Salesforce (CRM), Home Depot (HD), Chevron (CVX), CocaCola (KO), Meta Platforms (META), QUALCOMM (QCOM) and AbbVie (ABBV).

Company Calendar

Last Earnings
5/14/2025
Today
6/23/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INZY
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.75
High Stock Price Target
$23.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+194.5%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$102.02 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.90 per share
Price / Book
4.43

Miscellaneous

Free Float
56,698,000
Market Cap
$257.59 million
Optionable
Optionable
Beta
2.27
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:INZY) was last updated on 6/23/2025 by MarketBeat.com Staff
From Our Partners